SCHEMBL20839734

SCHEMBL20839734

COCCOc1cc(Cl)nnc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
POLB P06746 2/20 0.41
ALDH1A1 P00352 5/20 0.40
S1PR4 O95977 1/20 0.38
HTR2C P28335 2/20 0.38
HTR2B P41595 1/20 0.38
HPGD P15428 2/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.36
KDM1A O60341 2/20 0.35
RAB9A P51151 1/20 0.35
FLT1 P17948 3/20 0.34
KDR P35968 3/20 0.34
FGFR1 P11362 2/20 0.34
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25880792 0.83 ENPP1 (0.43) L3MBTL1POLBALDH1A1S1PR4HTR2C
SCHEMBL30042712 0.80 TDP1 (0.35) ALDH1A1TDP1LMNA
SCHEMBL2767989 0.79 TDP1 (0.38) L3MBTL1ALDH1A1S1PR4TDP1LMNA
SCHEMBL22445196 0.79 TDP1 (0.38) TDP1
SCHEMBL30936658 0.79 TDP1 (0.38) TDP1
SCHEMBL30310964 0.79 TDP1 (0.38) L3MBTL1ALDH1A1S1PR4TDP1LMNA
SCHEMBL22042604 0.79 FLT1 (0.36) PLAUL3MBTL1POLBALDH1A1HTR2C
SCHEMBL23530022 0.79 ALDH1A1 (0.41) L3MBTL1POLBALDH1A1HTR2CHTR2B
SCHEMBL29549805 0.79 ALDH1A1 (0.41) L3MBTL1POLBALDH1A1HTR2CHTR2B
SCHEMBL25880892 0.78 TDP1 (0.36) L3MBTL1ALDH1A1S1PR4TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3684776-B1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE UNIV NOTTINGHAM (GB) 2023-11-01 EP disclosed
US-11407767-B2 Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase UNIV NOTTINGHAM (GB) 2022-08-09 US disclosed
US-20200247824-A1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE THE UNIVERSITY OF NOTTINGHAM (GB) 2020-08-06 US disclosed
EP-3684776-A1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE The University of Nottingham (GB) 2020-07-29 EP disclosed
WO-2019058132-A1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE THE UNIVERSITY OF NOTTINGHAM (GB) 2019-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247824-A1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE CDK1, CDK11A, CDK12 PLAU 3632/4885L3MBTL1 882/4885POLB 69/4885
US-11407767-B2 Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase CDK1, CDK11A, CDK12 PLAU 3632/4885L3MBTL1 882/4885POLB 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.